Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints

06/09/2020
by   Cong Shen, et al.
0

Phase I dose-finding trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds (or combination of them) becomes more complex. Despite this, most commonly used methods in practice focus on identifying a Maximum Tolerated Dose (MTD) by learning only from toxicity events. We present a novel adaptive clinical trial methodology, called Safe Efficacy Exploration Dose Allocation (SEEDA), that aims at maximizing the cumulative efficacies while satisfying the toxicity safety constraint with high probability. We evaluate performance objectives that have operational meanings in practical clinical trials, including cumulative efficacy, recommendation/allocation success probabilities, toxicity violation probability, and sample efficiency. An extended SEEDA-Plateau algorithm that is tailored for the increase-then-plateau efficacy behavior of molecularly targeted agents (MTA) is also presented. Through numerical experiments using both synthetic and real-world datasets, we show that SEEDA outperforms state-of-the-art clinical trial designs by finding the optimal dose with higher success rate and fewer patients.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
03/12/2018

An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity

For many years Phase I and Phase II clinical trials were conducted separ...
research
06/29/2019

trialr: Bayesian Clinical Trial Designs in R and Stan

This manuscript introduces an R package called trialr that implements a ...
research
08/11/2022

Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?

In parametric Bayesian designs of early phase cancer clinical trials wit...
research
01/26/2021

SDF-Bayes: Cautious Optimism in Safe Dose-Finding Clinical Trials with Drug Combinations and Heterogeneous Patient Groups

Phase I clinical trials are designed to test the safety (non-toxicity) o...
research
07/16/2018

Improving Safety of the Continual Reassessment Method via a Modified Allocation Rule

This paper proposes a novel criterion for the allocation of patients in ...
research
03/17/2019

On Multi-Armed Bandit Designs for Phase I Clinical Trials

We study the problem of finding the optimal dosage in a phase I clinical...
research
11/26/2021

ESCADA: Efficient Safety and Context Aware Dose Allocation for Precision Medicine

Finding an optimal individualized treatment regimen is considered one of...

Please sign up or login with your details

Forgot password? Click here to reset